1439367-44-8

Basic information

• Product Name: 4-cyclohexylbutyl 2-oxopyridine-1(2H)-carboxylate
• Synonyms: 4-cyclohexylbutyl 2-oxopyridine-1(2H)-carboxylate
• CAS NO: 1439367-44-8
• Molecular Weight: 277.364
• Mol File: 1439367-44-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 4-cyclohexylbutyl 2-oxopyridine-1(2H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 4-cyclohexylbutyl 2-oxopyridine-1(2H)-carboxylate(1439367-44-8)
• EPA Substance Registry System: 4-cyclohexylbutyl 2-oxopyridine-1(2H)-carboxylate(1439367-44-8)

Safety Data

• Hazardous Substances Data: 1439367-44-8(Hazardous Substances Data)

Upstream product

• 1659-31-0 2,2'-dipyridyl carbonate 
• 4441-57-0 4-cyclohexylbutan-1-ol 

Downstream Products

• 4441-57-0 4-cyclohexylbutan-1-ol 

Relevant articles and documents

Progress in the development of β-lactams as N-Acylethanolamine Acid Amidase (NAAA) inhibitors: Synthesis and SAR study of new, potent N-O-substituted derivatives

The anti-inflammatory effects resulting from raising the levels of palmitoylethanolamide (PEA), an endogenous bioactive lipid, led to envisage N-Acylethanolamine Acid Amidase (NAAA), the cysteine hydrolase mainly responsible for PEA degradation, as an att

Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA)

The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

Synthesis, biological evaluation, and 3D QSAR study of 2-methyl-4-oxo-3-oxetanylcarbamic acid esters as N -acylethanolamine acid amidase (NAAA) inhibitors

N-(2-Oxo-3-oxetanyl)carbamic acid esters have recently been reported to be noncompetitive inhibitors of the N-acylethanolamine acid amidase (NAAA) potentially useful for the treatment of pain and inflammation. In the present study, we further explored the